In vivo evidence that the cannabinoid receptor 2–63 RR variant is associated with the acquisition and/or expansion of HIV infection

C Sagnelli, C Uberti-Foppa, H Hasson, G Bellini, C Minichini, S Salpietro, E Messina, D Barbanotti, M Merli, F Punzo, N Coppola, A Lazzarin, E Sagnelli, F Rossi

Research output: Contribution to journalArticle

Abstract

Objectives: The aim of the study was to investigate whether the rs35761398 variants of the cannabinoid receptor 2 (CB2) gene may influence the acquisition of HIV infection and the clinical presentation of HIV/hepatitis C virus (HCV) coinfection. Methods: We compared 166 HIV/HCV-coinfected patients with 186 HCV-monoinfected patients, all with biopsy-proven chronic hepatitis (using the Ishak scoring system), naïve for anti-HCV treatment and tested for the CB2 rs35761398 polymorphism (using the TaqMan assay). Results: The HIV/HCV-coinfected patients were more frequently male (P 
Original languageEnglish
Pages (from-to)597-604
Number of pages8
JournalHIV Medicine
Volume19
Issue number9
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'In vivo evidence that the cannabinoid receptor 2–63 RR variant is associated with the acquisition and/or expansion of HIV infection'. Together they form a unique fingerprint.

  • Cite this

    Sagnelli, C., Uberti-Foppa, C., Hasson, H., Bellini, G., Minichini, C., Salpietro, S., Messina, E., Barbanotti, D., Merli, M., Punzo, F., Coppola, N., Lazzarin, A., Sagnelli, E., & Rossi, F. (2018). In vivo evidence that the cannabinoid receptor 2–63 RR variant is associated with the acquisition and/or expansion of HIV infection. HIV Medicine, 19(9), 597-604. https://doi.org/10.1111/hiv.12638